Stryker stock: buy or sell?
August 22nd, 2019
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine.
Should I buy Stryker stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Stryker stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Stryker stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 15 ratings published for SYK stock in the last month. The general sentiment of these ratings is bullish for SYK stock, with 13 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-26||Robert W. Baird||n/a||Outperform|
|2019-7-26||Piper Jaffray Companies||n/a||Overweight|
|2019-7-26||Piper Jaffray Companies||n/a||Overweight|
|2019-7-26||Credit Suisse Group||n/a||Outperform|
|2019-7-11||Credit Suisse Group||n/a||Outperform|
|2019-4-1||Wells Fargo & Co||n/a||Outperform|
Stryker stock analysis
Stryker decreased an ugly -0.34% and closed at $218.27.
Stryker decreased an ugly -0.34% and closed at $218.27. On July, SMA50d and SMA100d crossed up triggering a rise of 6.17%. Since price and SMA100d lines crossed up on June, SYK climbed $35.72 (19.57%). On Jul/26, SYK hit a new all time high, pushing higher than on July 25th tops. Check different trading setups that use ATHs as triggers.
Shares of Stryker closed this week at $218.27 and raised a slightly good 0.59%.
Observing the weekly chart, SYK marked an uptrend of rising tops and rising bottoms. Since its last top late July at $222.59, price slid and bounced up back from $204.25. Breaking down under $204.25 would cancel the current uptrend and it might test lower supports. Note that $222.59 might act as a resistance line. Not so far away is the last price record Stryker marked late July. Early March, SMA20w and SMA40w crossed up triggering a rise of 14.53%. Since late January when SYK stock price broke up the SMA40w line, it gained $53.37 (32.37%).
Stryker stock price history
Stryker IPO was on March 17th, 1980 at $0.08 per share1. Since then, SYK stock grew a 272,737.50%, with an average of 6,993.30% per year. If you had invested $1,000 in Stryker stock in 1980, it would worth $2,727,375.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Stryker stock historical price chart
SYK stock reached all-time highs on July/26 with a price of $222.59.
Stryker stock price target is $227.80How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 15 price targets for SYK stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-26||Robert W. Baird||Raises Target||$206.00||$239.00||16%|
|2019-7-26||Piper Jaffray Companies||Reiterates||$205.00||$240.00||17.1%|
|2019-7-26||Piper Jaffray Companies||Raises Target||$205.00||$240.00||17.1%|
|2019-7-26||Credit Suisse Group||Raises Target||$232.00||$237.00||2.2%|
|2019-7-26||Cantor Fitzgerald||Raises Target||$190.00||$230.00||21.1%|
|2019-7-26||Canaccord Genuity||Raises Target||$195.00||$233.00||19.5%|
|2019-7-16||Morgan Stanley||Raises Target||$218.00||$230.00||5.5%|
|2019-7-15||BTIG Research||Raises Target||n/a||$219.00||-|
|2019-7-11||Credit Suisse Group||Raises Target||$200.00||$232.00||16%|
|2019-4-24||Deutsche Bank||Raises Target||$181.00||$208.00||14.9%|
|2019-4-1||Wells Fargo & Co||Raises Target||$214.00||$219.00||2.3%|
|2019-3-4||Morgan Stanley||Raises Target||$200.00||$218.00||9%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on April, Stryker rocketed a dazzling 18.27%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an impressive gain of 9.30% to $13,601.00 M dollars. In the same way, its profit margin (compared to sales) boosted to 26.12%, that is $3,553.00 million. Stryker fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Stryker TTM sales up to March 2019 were $13,876.00 and earnings $3,522.00 M USD. When comparing this TTM figures with the last reported annuality, we can esteem Stryker business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, stepped up a slightly fine 2.02%. Regarding profit margin, Stryker stayed steady -0.74% to 26.12%
|2013||$9,020 M||-||$1,010 M11.2%||-|
|2014||$9,675 M||7.26%||$515 M5.3%||-49.01%|
|2015||$9,946 M||2.80%||$1,439 M14.5%||179.42%|
|2016||$11,325 M||13.86%||$1,647 M14.5%||14.45%|
|2017||$12,444 M||9.88%||$1,020 M8.2%||-38.07%|
|2018||$13,601 M||9.30%||$3,553 M26.1%||248.33%|
|TTM||$13,876 M||2.02%||$3,522 M25.4%||-0.87%|
Quarterly financial resultsStryker posted $3,516.00 million in sales for 2019-Q1, a -7.38% less compared to previous quarter. Reported quarter earnings marked $412.00 million with a profit margin of 11.72%. Profit margin plummed a -42.76% compared to previous quarter when profit margin was 54.48%. When comparing turnover to same quarter last year, Stryker sales marked an excellent increase and jumped a 8.49%.
|2017-Q2||$3,010 M||-||$391 M13.0%||-|
|2017-Q3||$3,010 M||0.00%||$434 M14.4%||11.00%|
|2017-Q4||$3,471 M||15.32%||$-249 M-7.2%||-157.37%|
|2018-Q1||$3,241 M||-6.63%||$443 M13.7%||-277.91%|
|2018-Q2||$3,322 M||2.50%||$452 M13.6%||2.03%|
|2018-Q3||$3,242 M||-2.41%||$590 M18.2%||30.53%|
|2018-Q4||$3,796 M||17.09%||$2,068 M54.5%||250.51%|
|2019-Q1||$3,516 M||-7.38%||$412 M11.7%||-80.08%|
Stryker ownershipWhen you are planning to buy shares of a stock, it's always worth to review its ownership structure.
Stryker shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 7.92% of all shares.
In case of Stryker stock, 76.13% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SYK stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$81.6 B||$44.5 B||$59.3 B||$45.1 B||$7.0 B|
|Total shares||373.8 M||510.2 M||1,390.0 M||208.1 M||66.7 M|
|Float shares||328.5 M||509.5 M||1,390.0 M||206.6 M||66.6 M|
|- Institutional holdings (%)||76.1%||88.2%||93.4%||0.0%||86.3%|
|- Insider holdings (%)||7.9%||0.1%||0.2%||3.9%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$217.35 - $220.44|
|Average true range||$4.45|
|50d mov avg||$209.16|
|100d mov avg||$198.58|
|200d mov avg||$186.07|
Stryker performanceTo better understand Stryker performance you must compare its gains with other related stocks in same sector or industry. We compared Stryker against Baxter International, Boston Scientific, Edwards Lifesciences, Hill-Rom, Integra LifeSciences, Medtronic, Smith & Nephew SNATS, Wright Medical and Zimmer Biomet in the following table:
|SNNSmith & Nephew SN...||12.02%||25.64%||34.82%|
Stryker competitorsWe selected a few stocks to conform a list of Stryker competitors to check if you are interested in investing in SYK:
- Baxter International (BAX)
- Boston Scientific (BSX)
- Edwards Lifesciences (EW)
- Hill-Rom (HRC)
- Integra LifeSciences (IART)
- Medtronic (MDT)
- Smith & Nephew SNATS (SNN)
- Wright Medical (WMGI)
- Zimmer Biomet (ZBH)
Latest Stryker stock news
- InvestorPlaceStryker Earnings: SYK Stock Falls on Q1 EPS Beat, Weak Q2 GuidanceApril 23, 2019
- Seeking AlphaStryker Corporation: Cycle Insurance With Positive Growth OutlookNovember 18, 2018
- Seeking AlphaOn Stryker's ValueSeptember 13, 2018
- InvestorPlaceM&A News: Invuity Shares Soar on Stryker DealSeptember 11, 2018
- Seeking AlphaStryker: Aiming For 105% ReturnSeptember 3, 2018